Access cutting-edge hematologic malignancies treatment through this clinical trial at a research site in Springdale. Study-provided care at no cost to qualified participants.
Access hematologic malignancies specialists in Springdale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hematologic malignancies treatment provided free
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this hematologic malignancies clinical trial in Springdale, AR
If you're searching for hematologic malignancies treatment options in Springdale, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Springdale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematologic malignancies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.